Addex Therapeutics (ADXN) Competitors $7.64 -0.09 (-1.11%) As of 03/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. OVID, ATHE, PASG, LEXX, PLUR, COEP, MRNS, GDTC, CALC, and LGVNShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Ovid Therapeutics (OVID), Alterity Therapeutics (ATHE), Passage Bio (PASG), Lexaria Bioscience (LEXX), Pluri (PLUR), Coeptis Therapeutics (COEP), Marinus Pharmaceuticals (MRNS), CytoMed Therapeutics (GDTC), CalciMedica (CALC), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Ovid Therapeutics Alterity Therapeutics Passage Bio Lexaria Bioscience Pluri Coeptis Therapeutics Marinus Pharmaceuticals CytoMed Therapeutics CalciMedica Longeveron Ovid Therapeutics (NASDAQ:OVID) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Do analysts prefer OVID or ADXN? Ovid Therapeutics currently has a consensus price target of $3.03, indicating a potential upside of 700.56%. Addex Therapeutics has a consensus price target of $30.00, indicating a potential upside of 294.22%. Given Ovid Therapeutics' higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, OVID or ADXN? Ovid Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Does the media prefer OVID or ADXN? In the previous week, Ovid Therapeutics had 10 more articles in the media than Addex Therapeutics. MarketBeat recorded 13 mentions for Ovid Therapeutics and 3 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.96 beat Ovid Therapeutics' score of 0.37 indicating that Addex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, OVID or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Ovid Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$566K47.58-$52.34M-$0.38-1.00Addex Therapeutics$556.05K14.51-$11.76M-$0.34-22.38 Do institutionals and insiders hold more shares of OVID or ADXN? 72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 13.3% of Ovid Therapeutics shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in OVID or ADXN? Ovid Therapeutics received 342 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 70.97% of users gave Ovid Therapeutics an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote. CompanyUnderperformOutperformOvid TherapeuticsOutperform Votes35770.97% Underperform Votes14629.03% Addex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Is OVID or ADXN more profitable? Addex Therapeutics has a net margin of 850.30% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Addex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-5,142.56% -39.24% -26.19% Addex Therapeutics 850.30%-112.43%-77.95% SummaryOvid Therapeutics beats Addex Therapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.07M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-22.387.2023.1319.03Price / Sales14.51226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book6.346.476.944.33Net Income-$11.76M$141.90M$3.20B$247.06M7 Day Performance2.70%-3.05%-2.30%-0.52%1 Month Performance-10.47%-4.63%3.10%-3.73%1 Year Performance-38.38%-8.61%11.22%1.74% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.8135 of 5 stars$7.61-1.6%$30.00+294.2%-38.4%$8.07M$556,045.00-22.3830Short Interest ↓Gap UpOVIDOvid Therapeutics4.5317 of 5 stars$0.44+4.5%$3.03+582.7%-87.6%$31.58M$566,000.00-0.9560Analyst RevisionATHEAlterity Therapeutics2.7487 of 5 stars$3.54-6.1%$12.00+239.0%+76.2%$31.39MN/A0.0010Short Interest ↓News CoveragePositive NewsPASGPassage Bio3.2884 of 5 stars$0.50-0.2%$7.50+1,400.3%-68.5%$31.07MN/A-0.43130Positive NewsGap DownLEXXLexaria Bioscience3.2182 of 5 stars$1.76-0.6%$7.00+297.7%-52.8%$30.89M$496,923.00-3.527Gap UpPLURPluri1.0091 of 5 stars$4.38-0.5%N/A-38.1%$30.65M$678,000.00-0.78150Short Interest ↓Positive NewsGap DownCOEPCoeptis Therapeutics0.8165 of 5 stars$9.41-0.9%N/A+56.7%$30.51MN/A-1.622Positive NewsMRNSMarinus Pharmaceuticals2.3685 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageGDTCCytoMed Therapeutics2.4923 of 5 stars$2.64+1.1%$5.00+89.4%+0.7%$28.88MN/A0.00N/AShort Interest ↓Positive NewsCALCCalciMedica2.4954 of 5 stars$2.08+3.5%$18.00+765.4%-50.6%$28.04MN/A-1.9330Earnings ReportNews CoverageGap UpLGVNLongeveron2.3933 of 5 stars$1.86+0.5%$8.67+365.9%-45.7%$27.77M$2.39M-0.3020Short Interest ↑ Remove Ads Related Companies and Tools Related Companies Ovid Therapeutics Alternatives Alterity Therapeutics Alternatives Passage Bio Alternatives Lexaria Bioscience Alternatives Pluri Alternatives Coeptis Therapeutics Alternatives Marinus Pharmaceuticals Alternatives CytoMed Therapeutics Alternatives CalciMedica Alternatives Longeveron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
